The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1332
Iloperidone (Fanapt) - Another Second-Generation Antipsychotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

 

 

The FDA has approved the marketing of iloperidone (Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone (Risperdal, and others).

DRUGS FOR SCHIZOPHRENIA — First-generation antipsychotic agents block dopamine D2 receptors. Second-generation antipsychotics combine D2 and serotonin 5HT2A antagonism. Controlled trials have failed to demonstrate clear advantages in efficacy with the second-generation antipsychotics compared to less expensive first-generation drugs, except with clozapine, which has life-threatening adverse effects, and possibly with olanzapine, which has substantial adverse metabolic effects (REF 1,2). The second-generation drugs do have a relatively low ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Iloperidone (Fanapt) - Another Second-Generation Antipsychotic
Article code: 1332a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian